Dr. Ravi Rao has been a member of DBV’s Board of Directors since 2021. He is currently the Global Head of Research and Development and Chief Medical Officer at Swedish Orphan Biovitrum (Sobi) where he leads Sobi’s efforts to advance therapeutic treatments for rare diseases in hematology and immunology. Prior to Sobi, Dr. Rao was Chief Medical Officer at Aeglea Biotherapeutics and previously Vice President in Research and Development and Medical Affairs at GlaxoSmithKline and formerly held senior leadership positions at Roche. Before joining the pharmaceutical industry, he was an academic rheumatologist at Imperial College and a post-doctoral fellow at Harvard University. Dr. Rao is a Member of the Royal College of Physicians, London, and an Honorary Member of the Faculty of Pharmaceutical Medicine.